NECTIN4 (Nectin Cell Adhesion Molecule 4)

News alerts, weekly reports and conference planners

Entrez ID:

NECTIN4 expression	Urothelial Cancer	NECTIN4 expression	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2
NECTIN4 expression	Solid Tumor	NECTIN4 expression	Solid Tumor	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2
NECTIN4 expression	Urothelial Cancer	NECTIN4 expression	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
NECTIN4 expression	Urothelial Cancer	NECTIN4 expression	Urothelial Cancer	BT8009 Sensitive: C3 – Early Trials BT8009 Sensitive : C3	BT8009 Sensitive: C3 – Early Trials BT8009 Sensitive : C3
NECTIN4 underexpression	Urothelial Cancer	NECTIN4 underexpression	Urothelial Cancer	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D
NECTIN4 overexpression	Triple Negative Breast Cancer	NECTIN4 overexpression	Triple Negative Breast Cancer	9MW2821 Sensitive: D – Preclinical 9MW2821 Sensitive : D	9MW2821 Sensitive: D – Preclinical 9MW2821 Sensitive : D

Associations(6)